1 December 2023 false Taxfiler 2024.6 false 09295226business:PrivateLimitedCompanyLtd2023-12-012024-11-30 092952262023-11-30 092952262023-12-012024-11-30 09295226business:AuditExemptWithAccountantsReport2023-12-012024-11-30 09295226business:AbridgedAccounts2023-12-012024-11-30 092952262024-11-30 092952262023-11-30 09295226core:WithinOneYear2024-11-30 09295226core:WithinOneYear2023-11-30 09295226core:AfterOneYear2024-11-30 09295226core:AfterOneYear2023-11-30 09295226core:ShareCapitalcore:PreviouslyStatedAmount2024-11-30 09295226core:ShareCapitalcore:PreviouslyStatedAmount2023-11-30 09295226core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2024-11-30 09295226core:RetainedEarningsAccumulatedLossescore:PreviouslyStatedAmount2023-11-30 09295226core:PreviouslyStatedAmount2024-11-30 09295226core:PreviouslyStatedAmount2023-11-30 09295226business:SmallEntities2023-12-012024-11-30 09295226business:Director12023-12-012024-11-30 09295226countries:EnglandWales2023-12-012024-11-30 09295226business:RegisteredOffice2023-12-012024-11-30 09295226core:ComputerEquipment2023-12-012024-11-30 092952262022-12-012023-11-30 iso4217:GBP xbrli:pure
Company Registration No. 09295226 (England and Wales)
Rashed Pharma Ltd Unaudited accounts for the year ended 30 November 2024
Rashed Pharma Ltd Statement of financial position as at 30 November 2024
2024 
2023 
Notes
£ 
£ 
Current assets
Cash at bank and in hand
253 
8,117 
Creditors: amounts falling due within one year
(21,009)
(19,028)
Net current liabilities
(20,756)
(10,911)
Total assets less current liabilities
(20,756)
(10,911)
Creditors: amounts falling due after more than one year
- 
(6,527)
Net liabilities
(20,756)
(17,438)
Capital and reserves
Called up share capital
20 
20 
Profit and loss account
(20,776)
(17,458)
Shareholders' funds
(20,756)
(17,438)
For the year ending 30 November 2024 the company was entitled to exemption from audit under section 477 of the Companies Act 2006 relating to small companies. The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.
The director acknowledges his responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.
The members have agreed to the preparation of abridged accounts for the year in accordance with Section 444(2A).
These accounts have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies' regime and in accordance with the provisions of FRS 102 Section 1A - Small Entities. The profit and loss account has not been delivered to the Registrar of Companies.
The financial statements were approved by the Board and authorised for issue on 21 August 2025 and were signed on its behalf by
Mr Mohammed Rashed Director Company Registration No. 09295226
- 2 -
Rashed Pharma Ltd Notes to the Accounts for the year ended 30 November 2024
1
Statutory information
Rashed Pharma Ltd is a private company, limited by shares, registered in England and Wales, registration number 09295226. The registered office is 23 Prestwich Drive, Huddersfield, HD2 2NU, England. The company is in the process of being wound up.
2
Compliance with accounting standards
The accounts have been prepared in accordance with the provisions of FRS 102 Section 1A Small Entities. There were no material departures from that standard.
3
Accounting policies
The principal accounting policies adopted in the preparation of the financial statements are set out below and have remained unchanged from the previous year, and also have been consistently applied within the same accounts.
Basis of preparation
The accounts have been prepared prepared on a 'liquidation' (or 'break-up') basis.
Presentation currency
The accounts are presented in £ sterling.
Turnover
Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. Turnover from the sale of goods is recognised when goods have been delivered to customers such that risks and rewards of ownership have transferred to them. Turnover from the rendering of services is recognised by reference to the stage of completion of the contract. The stage of completion of a contract is measured by comparing the costs incurred for work performed to date to the total estimated contract costs.
Tangible fixed assets and depreciation
Tangible assets are included at cost less depreciation and impairment. Depreciation has been provided at the following rates in order to write off the assets over their estimated useful lives:
Computer equipment
25% on cost.
Going concern
The company is being wound up by members voluntarily.
4
Tangible fixed assets
Total 
£ 
Cost or valuation
At 1 December 2023
1,000 
Disposals
(1,000)
At 30 November 2024
- 
Depreciation
At 1 December 2023
1,000 
On disposals
(1,000)
At 30 November 2024
- 
Net book value
At 30 November 2024
- 
- 3 -
Rashed Pharma Ltd Notes to the Accounts for the year ended 30 November 2024
5
Average number of employees
During the year the average number of employees was 0 (2023: 0).
- 4 -